جست‌وجوی استاد و پژوهشگر

• Epigenetics
• Medicinal Chemistry
• Oncology
• +۳ مورد دیگر

Antonello Mai is a Full Professor in the Department of Pharmaceutical Chemistry and Technology at Sapienza University of Rome's Faculty of Pharmacy and Medicine. He teaches Pharmaceutical and Toxicological Chemistry and leads research on epigenetic modulators for cancer, neurodegenerative disorders, and infectious diseases. His work has yielded 400+ publications and major grants, including a €673,600 FISR project on methylome dysregulation in cancer. Research interests focus on: Epigenetic drug design (HDAC, SIRT, DNMT inhibitors) Anticancer mechanisms and drug resistance Antiviral/antimicrobial compound development Recent publications emphasize sirtuin modulators, HDAC inhibitors, and RNA epigenetics, revealing trends toward translational applications in oncology and infection biology. Honors include: Membership in the Italian Chemical Society (since 1992) Executive roles in European medicinal chemistry organizations ANVUR accreditation for academic quality oversight He has advised doctoral students as Coordinator of Sapienza's Pharmaceutical Sciences PhD program (2012–2018) and secured NIH/AIRC funding for epigenetic drug discovery. His team explores mitochondrial sirtuins and metastasis pathways.

• Medicinal Chemistry
• Epigenetics
• Cancer Research
• +۳ مورد دیگر

Sergio Valente is an Associate Professor in Medicinal Chemistry at the Department of Chemistry and Pharmacy Technology , Faculty of Pharmacy and Medicine, Sapienza University of Rome. His research focuses on epigenetic modulators for cancer, neurodegenerative, and parasitic diseases. He leads the Laboratory 256 dedicated to organic compound synthesis and characterization. Abilitations: National Scientific Abilitation (ASN, MIUR) for Associate Professor (2015) Education: PhD in 'Pasteur Science' (2007), cum laude degree in Pharmacy (2003) His research develops small molecule inhibitors for HDACs, SIRTs, HMTs, KDMs, and DNMTs, targeting: Anticancer chemotherapy Neurodegenerative disorders Metabolic pathologies Antiparasitic treatments Recent publications highlight: Development of SIRT5 activators for cardioprotection HDAC1-3 inhibitors in viral infection response Novel quinoline-based epigenetic modulators Dual-targeting strategies for LSD1/PRMT5 inhibition HDAC3's role in rhabdomyosarcoma radioresistance Scientific Recognition: Recipient of the National Prize for Medicinal Chemistry Research (2017, Italian Chemical Society). Grant Leadership: Coordinator of Ateneo 2015 Sapienza Project for LSD1 inhibitors and chemoproteomic probes.

Fatih Mehmet Erdurمشاهده پروفایل

دانشیار

• Nephrology
• Internal Medicine
• Kidney Transplantation
• +۵ مورد دیگر

Fatih Mehmet Erdur serves as an Associate Professor in the Department of Internal Medicine Sciences at Gaziantep University School of Medicine. His academic career spans multiple Turkish institutions including Necmettin Erbakan University, Yuzuncu Yıl University, and Istanbul University's Cerrahpasa Faculty of Medicine. He completed his medical education at Istanbul University in 2001, followed by specialization in Internal Medicine and Nephrology through residencies at Istanbul University (2002-2009), Yuzuncu Yıl University (2010-2013), and Necmettin Erbakan University (2013-2014). Medical Degree: Istanbul University Cerrahpasa Faculty of Medicine (1995-2001) Internal Medicine Specialization: Istanbul University (2002-2009) Nephrology Subspecialization: Yuzuncu Yıl University (2010-2013) Nephrology Fellowship: Necmettin Erbakan University (2013-2014) Dr. Erdur's research focuses on nephrology with particular emphasis on hemodialysis complications, kidney transplantation outcomes, cardiovascular manifestations in renal disease, and molecular mechanisms in diabetic nephropathy. His work bridges clinical practice with molecular investigations into oxidative stress, endothelial dysfunction, and genetic factors affecting renal outcomes. He has contributed significantly to understanding crush syndrome in earthquake victims, a critical area given Turkey's seismic activity. His publication portfolio shows consistent research output with recent work concentrating on immunologic risk in transplantation, cognitive function in dialysis patients, and biomarkers for predicting complications. The research demonstrates a clear trajectory from basic science investigations toward clinically applicable findings that improve patient management in renal care. Dr. Erdur has supervised multiple graduate theses focusing on high-immunologic-risk transplantation, bone loss in transplant recipients, and staging systems for myeloma-related kidney failure. His educational contributions include participation in numerous national and international nephrology conferences and specialized training programs including the European Renal Association congress and Turkish Nephrology Association winter schools. Professional affiliations include membership in the Turkish Nephrology Association (since 2014), European Renal Association-European Dialysis and Transplant Association (since 2014), and Turkish Medical Association (since 2002). His clinical experience spans nephrology positions at Gaziantep Dr. Ersin Arslan Training and Research Hospital (2017-2021), Bitlis State Hospital (2014-2017), and Yüksekova State Hospital (2009-2010).

Donald E. Ayerمشاهده پروفایل

استاد

• Gene Regulation
• Cancer Metabolism
• Transcription Factors
• +۶ مورد دیگر

Donald E. Ayer, PhD is a Professor in the Department of Oncological Sciences at the University of Utah , where he has been since 1995. He serves as Senior Director of Cancer Training and Career Enhancement at the Huntsman Cancer Institute and leads the Ayer Lab , focusing on transcriptional control of cancer metabolism. Key Research Areas: Myc transcription factor regulation, MondoA nutrient sensing, TXNIP role in glucose homeostasis, mitochondrial-nuclear communication, and metabolic reprogramming in cancer. Notable Collaborations: Work with Robert Eisenman (Fred Hutchinson Cancer Research Center), Richard Schlegel (University of Utah), and Cancer Genome Atlas Network. Education: PhD in Chemistry/Biochemistry from University of Colorado (1989), Postdoctoral training under Robert Eisenman at Fred Hutchinson (1989-1995). Scientific Contributions: Discovered MondoA and established its role in glucose sensing. Pioneered research on Myc-MondoA-TXNIP transcriptional network's impact on cancer cell proliferation and metabolic homeostasis. Developed bioluminescent sirtuin activity assays for drug discovery. Recent Publications highlight: 2024: Novel sirtuin activity assay for lysine deacylation 2023: TXNIP's role in Myc genomic binding in cancer 2021: Age-related MondoA decline in cellular senescence

Fengyi Wanمشاهده پروفایل

استاد

• Signal Transduction
• Pathogen-Host-Microbiota Interactions
• RNA-Binding Proteins
• +۳ مورد دیگر

Fengyi Wan , PhD, is a Professor in the Department of Biochemistry and Molecular Biology at the Johns Hopkins University School of Medicine . He also holds a joint appointment in the Molecular Microbiology and Immunology division. His research focuses on understanding the molecular mechanisms of host-pathogen-microbiota interactions in colon health and diseases, particularly mechanisms of signal transduction , RNA-binding proteins , colitis , and colon tumorigenesis . Education: PhD, Chinese Academy of Sciences (2003) BS, Wuhan University (1999) Research Interests : Wan's laboratory investigates how bacterial virulence factors manipulate host immune signaling (NF-κB, TAK1/IKK complex), epithelial barrier functions, and DNA damage responses. Current projects explore complement in breast milk modulating infant microbiota, genotoxins accelerating colon cancer, and adipokine signaling in inflammatory diseases. Recent publications highlight his expertise in NF-κB regulation through bacterial effectors (NleC, NleH), ribosomal protein S3 interactions, and RNA-binding protein Sam68's role in DNA repair and cancer. His work spans mechanistic studies in mouse models of colitis, tumorigenesis, and radiation injury. Scientific Recognition: Howard Temin Pathway to Independence Award (2008) American Cancer Society Research Scholar (2013) Johns Hopkins Catalyst Award (2017) Department of Defense Idea Development Award (2019) Wan's team actively recruits postdoctoral researchers and collaborates with institutions on microbiota-inflammation-cancer axis studies. The lab is located at 615 N. Wolfe Street, Room W8515, Baltimore, MD 21205.

Christian M. Matterمشاهده پروفایل

استاد

• Atherosclerosis
• Thrombosis
• Inflammation
• +۵ مورد دیگر

Christian M. Matter is a Professor of Cardiology at the University Hospital Zurich , where he leads Translational Research and the Cardio-oncology service . A board-certified internist and cardiologist with training in Lucerne, Zurich, and Boston, he combines basic research (using cell culture and genetic mouse models) with clinical studies in myocardial infarction, heart failure, and cancer patients. His work focuses on the intersection of inflammation , immunometabolism , and atherothrombosis . Research Interests: Immuno-metabolic pathways in atherothrombosis Role of PARP1, JNK2, Sirtuins 1/3/6 in cardiovascular disease Clonal Hematopoiesis of Indeterminate Potential (CHIP) in mice Machine learning-based risk prediction for ACS patients Cardio-oncology (immune checkpoint inhibitors, myocardial damage) Microbiome-immune-cardiovascular interactions Collaborative Projects: Co-PI of Special Program University Medicine (SPUM) ACS-inflammation cohort (5,000 patients) Main applicant for SwissHeart Failure Network (SHFN) with ETH Zurich's Joachim Buhmann Collaborations with dermatology (Reinhard Dummer), immunology (Burkhard Ludewig), and microbiome experts (Michael Scharl) Key Findings: Developed machine learning mortality prediction models for ACS patients Demonstrated SIRT3/SIRT6 protective roles in thrombosis and atherogenesis Elucidated PARP1/JNK2 mechanisms in endothelial dysfunction Identified FAP as atheroprotective target Grants & Collaborations: Funded by Swiss Academy of Medical Sciences (SAMW) Supported by Swiss Heart Foundation Industry partnerships with Novartis, Sanofi-Regeneron, Amgen Collaborative networks in Basel, Bern, Geneva

• Biochemistry
• Chemical Biology
• Redox Signaling
• +۷ مورد دیگر

Brian C. Smith, PhD, is an Associate Professor in the Department of Biochemistry at the Medical College of Wisconsin (MCW), with adjunct roles at Marquette University. His affiliations include leadership as Associate Director of the Program in Chemical Biology and memberships in MCW's Cancer Center, Cardiovascular Research Center, and Center for Disease Prevention Research. He holds a PhD from the University of Wisconsin-Madison and completed postdoctoral training at UC Berkeley and Scripps Research. Dr. Smith's research spans redox biochemistry , epigenetic regulation , and enzyme mechanisms , focusing on post-translational modifications like S-nitrosation and lysine acylation. His lab studies sirtuin deacetylases, BET bromodomains, and nitric oxide signaling using techniques such as mass spectrometry, NMR, and chemical probe development. Major themes include: Developing bromodomain inhibitors for diabetes and cancer Deciphering redox control of protein function Engineering selective epigenetic modulators His recent publications (2023–2025) emphasize BET bromodomain therapeutics , sirtuin oxidative regulation , and redox metabolism in disease , with frequent appearances in high-impact journals like J Biol Chem , Cell Chem Biol , and ACS Chemical Biology . Honors include: MCW Outstanding Graduate Educator Award (2018) MCW Faculty Service Award (2019) Phi Beta Kappa & Bronze Tablet (Top 3% graduate, UIUC) NIH F31/R35 grants with impact scores of 12–17 (top percentiles) He actively mentors PhD students and postdocs, with funded projects totaling over $3M from NIH, ADA, and AHA. His lab collaborates with cardiovascular and cancer research teams, leveraging MCW's core facilities in structural genomics and redox biology.

Jackson Taylorمشاهده پروفایل

استادیار

• Epigenetics
• Aging Research
• Longevity Mechanisms
• +۳ مورد دیگر

Jackson Taylor is an Assistant Professor at Cleveland State University's Center for Gene Regulation in Health and Disease (GRHD), leading research on epigenetic mechanisms of aging using Drosophila melanogaster models. His work focuses on how epigenetic modifications drive age-related dysfunction and disease, with emphasis on lifespan extension strategies. Education: Ph.D. in Neuroscience, Wake Forest University School of Medicine (2013) Postdoctoral Training, Wake Forest Health Sciences (2013-2016) Postdoctoral Training, Brown University (2016-2022) Dr. Taylor's research program investigates epigenome dynamics during aging, particularly how experimental manipulation of epigenetic regulators like Sirt6 extends lifespan and preserves physical function. His lab employs next-generation sequencing, bioinformatics, genetic engineering, and longevity assays to study Alzheimer's disease models and identify novel epigenetic modifiers. Key findings demonstrate that Sirt6 overexpression represses Myc target genes through H3K9ac deacetylation, reducing protein synthesis and extending lifespan in fruit flies. Analysis of his publication record reveals consistent focus on epigenetic aging mechanisms across model systems, with significant contributions to understanding transposable element regulation, DNA methylation patterns in immune aging, and calcium channel dynamics in sarcopenia. His work bridges basic epigenetic discovery with translational applications for age-related diseases. Dr. Taylor advises graduate students in the Taylor Lab (established Fall 2022), mentoring Samira Xhaferi, Roja Sharma, and Prema Singaravel. His research is supported through GRHD center resources and collaborations with the Cleveland Clinic Joint Ph.D. Programs. The Taylor Lab operates within CSU's Science and Research Building (Room 259), utilizing advanced genomic and bioinformatic infrastructure through the GRHD center's facilities. Current projects target tissue-specific Sirt6 mechanisms in Alzheimer's disease models and high-throughput screening of epigenetic longevity modifiers.